In a phase 1 clinical trial that tested safety and immunogenicity in patients with ovarian cancer and breast cancer who had achieved remission, vaccination utilizing a multi-epitope FRα peptide vaccine was considered safe, producing mostly injection-site reactions and showing no association with grade 3 toxicity [44]. This evidence concerns the gene FOLR1 and ovarian carcinoma.